Nephrol Dial Transplant (2001) 16: 1047-1052
© 2001 European Renal Association-European Dialysis and Transplant Association
Brief Reports
Metabolic cardiovascular syndrome after renal transplantation
1 Departments of Medicine, 2 Cardiology, 3 Clinical Chemistry, 4 Centre of Clinical Epidemiology, National Hospital, University of Oslo, Oslo, Norway
Background. Cardiovascular disease (CVD) is the major cause of death in renal transplant recipients. Traditional risk factors like hypertension, dyslipidaemia and diabetes mellitus are common, but cannot completely account for the high prevalence of CVD in this population. The aim of the present study was to assess whether post-transplant glucose intolerance, defined as post-transplant diabetes mellitus, impaired glucose tolerance, or impaired fasting glucose, is associated with metabolic disturbances known to increase risk of cardiovascular disease, similar to what has been observed in the general population.
Methods. One hundred and seventy-three consecutive patients were prospectively examined 10 weeks after transplantation. An oral glucose tolerance test was completed in 167 patients. Questionnaires, medical records, and the results of various blood tests were used to evaluate a number of known cardiovascular risk factors in all patients.
Results. Glucose intolerance was present in about one-half the recipients and was associated with age, a positive family history of ischaemic heart disease, acute rejection, higher levels of serum triglycerides, apolipoprotein B and 2-h insulin, and lower levels of serum HDL cholesterol. After adjustment for age and sex, lower HDL cholesterol (P=0.005), higher serum triglycerides (P<0.001), apolipoprotein B (P=0.039) and 2-h insulin (P<0.001) were still associated with post-transplant glucose intolerance.
Conclusions. Ten weeks after renal transplantation glucose intolerance is associated with a clustering of cardiovascular risk factors and metabolic abnormalities, consistent with a post-transplant metabolic cardiovascular syndrome.
Keywords: cardiovascular disease; cardiovascular metabolic syndrome; dyslipidaemia; post-transplant diabetes mellitus; post-transplant glucose intolerance; renal transplantation
Correspondence and offprint requests to: Jøran Hjelmesæth, Medical Department, Vestfold Central Hospital, Boks 2168, N-3103 Tønsberg, Norway.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. Delgado, J. M. Diaz, I. Silva, J. M. Osorio, A. Osuna, B. Bayes, R. Lauzurica, E. Arellano, J. M. Campistol, R. Dominguez, et al. Unmasking Glucose Metabolism Alterations in Stable Renal Transplant Recipients: A Multicenter Study Clin. J. Am. Soc. Nephrol., May 1, 2008; 3(3): 808 - 813. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Guida, R. Trio, R. Laccetti, A. Nastasi, E. Salvi, N. R. Perrino, C. Caputo, E. Rotaia, S. Federico, and M. Sabbatini Role of dietary intervention on metabolic abnormalities and nutritional status after renal transplantation Nephrol. Dial. Transplant., November 1, 2007; 22(11): 3304 - 3310. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Hjelmesaeth, T. Ueland, A. Flyvbjerg, J. Bollerslev, T. Leivestad, T. Jenssen, T. K. Hansen, S. Thiel, S. Sagedal, J. Roislien, et al. Early Posttransplant Serum Osteoprotegerin Levels Predict Long-Term (8-Year) Patient Survival and Cardiovascular Death in Renal Transplant Patients J. Am. Soc. Nephrol., June 1, 2006; 17(6): 1746 - 1754. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Hjelmesaeth, A. Flyvbjerg, T. Jenssen, J. Frystyk, T. Ueland, M. Hagen, and A. Hartmann Hypoadiponectinemia Is Associated with Insulin Resistance and Glucose Intolerance after Renal Transplantation: Impact of Immunosuppressive and Antihypertensive Drug Therapy Clin. J. Am. Soc. Nephrol., May 1, 2006; 1(3): 575 - 582. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H. Voytovich, C. Simonsen, T. Jenssen, J. Hjelmesaeth, A. Asberg, and A. Hartmann Short-term treatment with rosiglitazone improves glucose tolerance, insulin sensitivity and endothelial function in renal transplant recipients Nephrol. Dial. Transplant., February 1, 2005; 20(2): 413 - 418. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Midtvedt, J. Hjelmesaeth, A. Hartmann, K. Lund, D. Paulsen, T. Egeland, and T. Jenssen Insulin Resistance after Renal Transplantation: The Effect of Steroid Dose Reduction and Withdrawal J. Am. Soc. Nephrol., December 1, 2004; 15(12): 3233 - 3239. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Hagen, J. Hjelmesaeth, T. Jenssen, L. Morkrid, and A. Hartmann A 6-year prospective study on new onset diabetes mellitus, insulin release and insulin sensitivity in renal transplant recipients Nephrol. Dial. Transplant., October 1, 2003; 18(10): 2154 - 2159. [Abstract] [Full Text] [PDF]
|
|